Rubius Therapeutics (OTCPK:RUBY) - Hisse Senedi Fiyatı, Haberler ve Analizler

RUBY Stoklara Genel Bakış

Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases.

Şirket hakkında

RUBY temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Ödüller

Risk Analizi

Anlamlı bir piyasa değeri yok ( $5M )

Geliri 1 milyon ABD dolarından az ( $0 )

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Son mali raporlar 6 aydan daha eskidir

Rubius Therapeutics, Inc. Rakipler

Creative Medical Technology Holdings

NasdaqCM:CELZ

US$5.4m

Galmed Pharmaceuticals

NasdaqCM:GLMD

US$4.9m

Exicure

NasdaqCM:XCUR

US$5.8m

Silo Pharma

NasdaqCM:SILO

US$4.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Rubius Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.057
52 Haftanın En Yüksek Seviyesi	US$0.38
52 Haftanın En Düşük Seviyesi	US$0.0032
Beta	2.21
11 Aylık Değişim	198.43%
3 Aylık Değişim	251.85%
1 Yıllık Değişim	-64.38%
33 Yıllık Değişim	-99.32%
5 Yıllık Değişim	-99.63%
Halka arzdan bu yana değişim	-99.76%

Son Haberler & Güncellemeler

Recent updates

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Oct 28

Our Read On Rubius Therapeutics

Jul 11

Rubius Therapeutics EPS beats by $0.02

May 10

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Feb 25

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Rubius Therapeutics EPS misses by $0.01

Nov 09

Rubius Therapeutics' RTX-321 shows dual mechanism of action in HPV-positive cancers

Oct 28

Hissedar Getirileri

	RUBY	US Biotechs	US Pazar
7D	2.7%	-1.4%	-1.9%
1Y	-64.4%	20.2%	30.4%

Getiri vs. Endüstri: RUBY geçen yıl % 20.2 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: RUBY geçen yıl % 30.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is RUBY's price volatile compared to industry and market?
RUBY volatility
RUBY Average Weekly Movement	54.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: RUBY hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: RUBY 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 34% dan 55% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	6	Craig Jalbert	www.rubiustx.com

Rubius Therapeutics, Inc. Temel Bilgiler Özeti

Rubius Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RUBY temel i̇stati̇sti̇kler
Piyasa değeri	US$5.16m
Kazançlar(TTM)	-US$179.67m
Gelir(TTM)	n/a

0.0x

P/S Oranı

0.0x

F/K Oranı

RUBY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RUBY gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$179.67m
Kazançlar	-US$179.67m

Son Raporlanan Kazançlar

Dec 31, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-1.99
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

RUBY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RUBY Stoklara Genel Bakış

Ödüller

Risk Analizi

Rubius Therapeutics, Inc. Rakipler

NasdaqCM:CELZ

US$5.4m

NasdaqCM:GLMD

US$4.9m

NasdaqCM:XCUR

US$5.8m

NasdaqCM:SILO

US$4.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Price target increased to US$7.63

Recent updates

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

High number of new and inexperienced directors

Rubius Therapeutics, Inc. Announces Leadership Changes

Rubius Therapeutics, Inc. Announces Resignation of David Epstein as a Member of the Board

Rubius Therapeutics Announces Strategic Update

Price target increased to US$7.63

Rubius Therapeutics, Inc. Announces Resignation of Natalie Holles as Member of the Board of Directors

Price target increased to US$10.33

Rubius Therapeutics GAAP EPS of -$0.49 beats by $0.03

Rubius Therapeutics Receives Non-Compliance Letter from Nasdaq

Rubius Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Rubius Therapeutics, Inc. Appoints Susanne Schaffert to Its Board of Directors

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 2000 Growth Index

Rubius: Poor Data, Punishing Environment, Beaten Stock

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

Price target decreased to US$7.60

Price target decreased to US$8.67

Price target decreased to US$9.40

Price target increased to US$23.00

Rubius Therapeutics, Inc. Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

Rubius Therapeutics, Inc., Annual General Meeting, May 12, 2022

Rubius Looks Attractive Before AACR Data Readout

Price target increased to US$23.00

Rubius Therapeutics, Inc. to Report Q4, 2021 Results on Feb 25, 2022

Price target decreased to US$21.33

Price target decreased to US$23.33

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the Treatment of Certain Solid Tumors

Price target decreased to US$25.67

Rubius Therapeutics to Highlight the Power of RED PLATFORM®, Significant Advances Across Red Cell Therapeutic Oncology Pipeline and New Type 1 Diabetes Program at Platform and Pipeline Day

Are Rubius Therapeutics, Inc. (NASDAQ:RUBY) Investors Paying Above The Intrinsic Value?

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Our Read On Rubius Therapeutics

Rubius Therapeutics, Inc.(NasdaqGS:RUBY) dropped from Russell 3000E Value Index

Rubius Therapeutics, Inc. Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® in Ongoing Phase 1/2 Clinical Trial for Treatment of Advanced Solid Tumors

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Rubius Therapeutics EPS beats by $0.02

Insider exercised options and sold US$313k worth of stock

Rubius Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity

Rubius Therapeutics Announces Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240

New 90-day high: US$15.01

Have Insiders Been Buying Rubius Therapeutics, Inc. (NASDAQ:RUBY) Shares?

Price target raised to US$13.25

Executive Chairman notifies of intention to sell stock

Rubius Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: US$10.00

Price target raised to US$10.29

Rubius Therapeutics (RUBY) Presents At 39th Annual Healthcare Conference - Slideshow

Rubius Therapeutics, Inc. Provides an Operational Update

New 90-day high: US$8.83

New 90-day high: US$8.73

New 90-day high: US$5.92

Rubius Therapeutics Presents Preclinical Data for Lead Red Cell Therapeutic Clinical Oncology Program, Rtx-240, at the Society for Immunotherapy of Cancer’s Annual Meeting

Rubius Therapeutics EPS misses by $0.01

Rubius Therapeutics, Inc. Announces Dosing of First Patient with Relapsed/Refractory Acute Myeloid Leukemia in the Ongoing Phase 1/2 Clinical Trial of RTX-240

Rubius Therapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020